Abiopharma

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

EUDA Accelerates Longevity Strategy with Launch of Comprehensive Stem Cell Therapy Platform and First Clinic in Shenzhen

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

インサイト・ジャパン、再発・難治性濾胞性リンパ腫の治療を対象に、リツキシマブおよびレナリドミドとの併用療法として「ミンジュビ®（タファシタマブ）」の承認取得を発表

Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment

Appendix 3Y for Gregory George

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma